Skip to main content

Advertisement

SpringerLink
Log in

DEMENTIA

Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia

  • News & Views
  • Published:

From Nature Aging

View current issue Submit your manuscript

Accurate blood tests for Alzheimer’s disease (AD) are critical tools that have the potential to revolutionize dementia research, clinical trials and clinical care. Models combining blood-based biomarkers that represent multiple aspects of AD brain pathology with key individual level factors may improve prediction of AD dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Predicting progression to dementia using a single biomarker cut-off versus a multivariate model.

References

  1. Nakamura, A. et al. Nature 554, 249–254 (2018).

    Article  CAS  Google Scholar 

  2. Ovod, V. et al. Alzheimers. Dement. 13, 841–849 (2017).

    Article  Google Scholar 

  3. Schindler, S. E. et al. Neurology 93, e1647–e1659 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Palmqvist, S. et al. JAMA 324, 772–781 (2020).

    Article  CAS  Google Scholar 

  5. Mielke, M. M. et al. Alzheimers. Dement. 14, 989–997 (2018).

    Article  Google Scholar 

  6. Barthelemy, N. R., Horie, K., Sato, C. & Bateman, R. J. J. Exp. Med. 217, e20200861 (2020).

    Article  Google Scholar 

  7. Janelidze, S. et al. Nat. Med. 26, 379–386 (2020).

    Article  CAS  Google Scholar 

  8. Karikari, T. K. et al. Lancet Neurol. 19, 422–433 (2020).

    Article  CAS  Google Scholar 

  9. Preische, O. et al. Nat. Med. 25, 277–283 (2019).

    Article  CAS  Google Scholar 

  10. Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. JAMA Neurol. 76, 791–799 (2019).

    Article  Google Scholar 

  11. Cullen, N. C. et al. Nat. Aging https://doi.org/10.1038/s43587-020-00003-5 (2020).

  12. Karran, E. & Hardy, J. N. Engl. J. Med. 370, 377–378 (2014).

    Article  CAS  Google Scholar 

  13. Bateman, R. J. & Klunk, W. E. Neurotherapeutics 5, 381–390 (2008).

    Article  CAS  Google Scholar 

  14. Sperling, R. A. et al. Sci. Transl. Med. 6, 228fs213 (2014).

    Article  Google Scholar 

  15. Rabinovici, G. D. et al. JAMA 321, 1286–1294 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

S.E.S. is supported by National Institute on Aging (grant no. K23AG053426).

Author information

Authors and Affiliations

  1. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

    Suzanne E. Schindler & Randall J. Bateman

  2. Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA

    Suzanne E. Schindler & Randall J. Bateman

  3. Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO, USA

    Randall J. Bateman

Authors
  1. Suzanne E. Schindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randall J. Bateman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suzanne E. Schindler.

Ethics declarations

Competing interests

R.J.B. co-founded C2N Diagnostics. Washington University and R.J.B. have equity ownership interest in C2N Diagnostics and receive royalty income based on technology (stable isotope labeling kinetics and blood plasma assay) licensed by Washington University to C2N Diagnostics. R.J.B. receives income from C2N Diagnostics for serving on the Scientific Advisory Board. Washington University, with R.J.B. as co-inventor, have filed patent applications (US Patent application nos. 16/610,428; 62/898,407; 62/962,296; PCT/US2020/012959) on technology related to the processes described in this article. R.J.B. has received honoraria as a speaker/consultant/advisory board member from Amgen, AC Immune, Eisai, F. Hoffman-LaRoche and Janssen, and reimbursement of travel expenses from AC Immune, F. Hoffman-La Roche and Janssen. S.E.S. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schindler, S.E., Bateman, R.J. Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia. Nat Aging 1, 26–28 (2021). https://doi.org/10.1038/s43587-020-00008-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43587-020-00008-0

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation